Corbus Pharmaceu Financials

CRBP

Export CSV

Key Financial Metrics

Revenue

N/A

EBITDA

-$48.1M

YoY-8.3%

Corbus Pharmaceu's EBITDA was -$48.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 8.3% from the prior year.

Free Cash Flow

N/A

Net Income

-$40.2M

YoY+9.9%

Corbus Pharmaceu reported -$40.2M in net income in fiscal year 2024. This represents an increase of 9.9% from the prior year.

EPS (Diluted)

$-3.68

YoY+64.3%

Corbus Pharmaceu earned $-3.68 per diluted share in fiscal year 2024. This represents an increase of 64.3% from the prior year.

Cash & Debt

$17.2M

YoY+25.3%

5Y CAGR-11.5%

10Y CAGR+10.6%

Corbus Pharmaceu held $17.2M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

12M

YoY+175.3%

5Y CAGR-28.4%

10Y CAGR-7.3%

Corbus Pharmaceu had 12M shares outstanding in fiscal year 2024. This represents an increase of 175.3% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$32.2M

YoY+3.4%

5Y CAGR-18.5%

10Y CAGR+38.3%

Corbus Pharmaceu invested $32.2M in research and development in fiscal year 2024. This represents an increase of 3.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

CRBP Income Statement

Metric	FY24	FY24	FY22	FY22	FY21	FY20
Revenue	N/A	N/A	$0-100.0%	$882K-77.6%	$3.9M-89.1%	$36.1M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$32.2M+3.4%	$31.2M+93.1%	$16.1M-55.7%	$36.4M-62.9%	$98.3M+9.7%	$89.6M
SG&A Expenses	$16.5M+18.6%	$13.9M-25.6%	$18.7M-8.5%	$20.4M-28.3%	$28.5M+20.5%	$23.6M
Operating Income	-$48.7M-8.1%	-$45.1M-13.2%	-$39.8M+28.9%	-$56.0M+54.4%	-$122.8M-59.3%	-$77.1M
Interest Expense	$1.8M-52.6%	$3.8M+22.7%	$3.1M+14.3%	$2.7M+140.5%	$1.1M	$0
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$40.2M+9.9%	-$44.6M-5.3%	-$42.3M+7.2%	-$45.6M+59.0%	-$111.3M-55.7%	-$71.5M
EPS (Diluted)	$-3.68+64.3%	$-10.31-1.6%	$-10.15+9.0%	$-11.15	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$20.9M+37.4%	$15.2M-2.9%	$15.6M	N/A	$10.8M+57.4%	$6.9M+19.1%	$5.8M	N/A
SG&A Expenses	$3.6M-10.3%	$4.0M-4.1%	$4.1M	N/A	$4.7M+13.9%	$4.1M+6.8%	$3.9M	N/A
Operating Income	-$24.4M-27.5%	-$19.2M+3.2%	-$19.8M	N/A	-$15.5M-41.1%	-$11.0M-14.2%	-$9.6M	N/A
Interest Expense	$0	$0	$0	N/A	$400K-33.3%	$600K-25.0%	$800K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$23.3M-32.2%	-$17.7M-4.0%	-$17.0M	N/A	-$13.8M-37.9%	-$10.0M-44.9%	-$6.9M	N/A
EPS (Diluted)	$-1.90-31.9%	$-1.44-3.6%	$-1.39	N/A	$-1.15-27.8%	$-0.90-8.4%	$-0.83	N/A

CRBP Balance Sheet

Metric	FY24	FY24	FY22	FY22	FY21	FY20
Total Assets	$155.9M+451.4%	$28.3M-57.4%	$66.3M-38.4%	$107.7M+5.3%	$102.3M+108.2%	$49.1M
Current Assets	$153.0M+549.7%	$23.5M-60.9%	$60.2M-39.9%	$100.2M+8.8%	$92.1M+141.3%	$38.2M
Cash & Equivalents	$17.2M+25.3%	$13.7M-19.3%	$17.0M-32.0%	$25.0M-70.7%	$85.4M+169.1%	$31.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$13.5M-61.8%	$35.2M+5.6%	$33.3M-13.7%	$38.6M-32.3%	$57.0M+32.7%	$43.0M
Current Liabilities	$11.8M-62.9%	$31.9M+152.3%	$12.6M-25.7%	$17.0M-46.7%	$31.9M-8.6%	$34.9M
Long-Term Debt	N/A	$0-100.0%	$16.0M+2.2%	$15.6M-13.3%	$18.0M	N/A
Total Equity	$142.4M+2162.7%	-$6.9M-120.9%	$33.0M-52.3%	$69.1M+52.6%	$45.3M+635.3%	$6.2M
Retained Earnings	-$476.9M-9.2%	-$436.7M-11.4%	-$392.1M-12.1%	-$349.7M-15.0%	-$304.1M-57.7%	-$192.8M

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$109.5M-12.4%	$125.1M-10.6%	$139.9M-10.2%	$155.9M-5.1%	$164.2M+8.0%	$152.0M+20.9%	$125.7M+344.8%	$28.3M
Current Assets	$107.6M-12.4%	$122.8M-10.6%	$137.4M-10.2%	$153.0M-4.9%	$160.9M+8.5%	$148.3M+21.9%	$121.7M+416.8%	$23.5M
Cash & Equivalents	$27.0M+34.6%	$20.0M+6.1%	$18.9M+9.9%	$17.2M-11.5%	$19.4M-18.0%	$23.7M+67.9%	$14.1M+2.8%	$13.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$17.4M+23.2%	$14.1M+9.9%	$12.8M-4.7%	$13.5M-1.6%	$13.7M-48.3%	$26.4M-8.1%	$28.8M-18.2%	$35.2M
Current Liabilities	$17.1M+28.0%	$13.3M+14.7%	$11.6M-1.7%	$11.8M+1.7%	$11.6M-51.5%	$24.0M-7.5%	$25.9M-18.7%	$31.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0
Total Equity	$92.1M-17.0%	$111.0M-12.7%	$127.1M-10.8%	$142.4M-5.4%	$150.5M+19.9%	$125.5M+29.5%	$97.0M+1504.3%	-$6.9M
Retained Earnings	-$534.9M-4.6%	-$511.5M-3.6%	-$493.9M-3.6%	-$476.9M-2.0%	-$467.4M-3.0%	-$453.6M-2.3%	-$443.6M-1.6%	-$436.7M

CRBP Cash Flow Statement

Metric	FY24	FY24	FY22	FY22	FY21	FY20
Operating Cash Flow	-$41.8M-15.8%	-$36.1M+3.8%	-$37.5M+22.1%	-$48.2M+51.7%	-$99.7M-118.0%	-$45.7M
Capital Expenditures	N/A	$0-100.0%	$13K-75.2%	$54K-88.8%	$484K-82.3%	$2.7M
Free Cash Flow	N/A	-$36.1M+3.9%	-$37.6M+22.1%	-$48.2M+51.8%	-$100.2M-106.7%	-$48.5M
Investing Cash Flow	-$121.3M-440.4%	$35.6M+18.5%	$30.1M+141.0%	-$73.4M-15053.3%	-$484K+82.3%	-$2.7M
Financing Cash Flow	$166.6M+6004.9%	-$2.8M-428.7%	-$534K-100.9%	$60.8M-60.7%	$154.9M+302.7%	$38.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	N/A	N/A	-$16.4M	N/A	N/A	N/A	-$8.0M	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	$18.1M	N/A	N/A	N/A	-$98.2M	N/A
Financing Cash Flow	N/A	N/A	$0	N/A	N/A	N/A	$106.6M	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CRBP Financial Ratios

Metric	FY24	FY24	FY22	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	-6350.1%-3230.9pp	-3119.2%-2905.9pp	-213.3%
Net Margin	N/A	N/A	N/A	-5176.4%-2350.3pp	-2826.1%-2628.4pp	-197.7%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-25.8%+132.0pp	-157.8%-93.9pp	-63.9%-21.5pp	-42.4%+66.4pp	-108.8%+36.6pp	-145.4%
Current Ratio	12.94+12.2	0.74-4.0	4.76-1.1	5.89+3.0	2.89+1.8	1.09
Debt-to-Equity	0.09+0.1	0.00-0.5	0.48+0.3	0.23-0.2	0.40-6.6	6.98
FCF Margin	N/A	N/A	N/A	-5471.0%-2926.8pp	-2544.2%-2410.1pp	-134.1%

Metric	Q3'25	Q2'25	Q1'25	Q3'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-21.3%-7.2pp	-14.1%-2.0pp	-12.1%	N/A	-8.4%-1.8pp	-6.6%-1.1pp	-5.5%	N/A
Current Ratio	6.31-2.9	9.21-2.6	11.82-1.1	12.94-0.9	13.84+7.7	6.18+1.5	4.69+4.0	0.74
Debt-to-Equity	0.19+0.1	0.13+0.0	0.100.0	0.090.0	0.09-0.1	0.21+0.2	0.000.0	0.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Frequently Asked Questions

Is Corbus Pharmaceu profitable?

No, Corbus Pharmaceu (CRBP) reported a net income of -$40.2M in fiscal year 2024.

What is Corbus Pharmaceu's earnings per share (EPS)?

Corbus Pharmaceu (CRBP) reported diluted earnings per share of $-3.68 for fiscal year 2024.

What is Corbus Pharmaceu's EBITDA?

Corbus Pharmaceu (CRBP) had EBITDA of -$48.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Corbus Pharmaceu's operating cash flow?

Corbus Pharmaceu (CRBP) generated -$41.8M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Corbus Pharmaceu's total assets?

Corbus Pharmaceu (CRBP) had $155.9M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Corbus Pharmaceu spend on research and development?

Corbus Pharmaceu (CRBP) invested $32.2M in research and development during fiscal year 2024.

How many shares does Corbus Pharmaceu have outstanding?

Corbus Pharmaceu (CRBP) had 12M shares outstanding as of fiscal year 2024.

What is Corbus Pharmaceu's current ratio?

Corbus Pharmaceu (CRBP) had a current ratio of 12.94 as of fiscal year 2024, which is generally considered healthy.

What is Corbus Pharmaceu's debt-to-equity ratio?

Corbus Pharmaceu (CRBP) had a debt-to-equity ratio of 0.09 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Corbus Pharmaceu's return on assets (ROA)?

Corbus Pharmaceu (CRBP) had a return on assets of -25.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.